Raptor Pharmaceutical Corp Company Profile (NASDAQ:RPTP)

About Raptor Pharmaceutical Corp (NASDAQ:RPTP)

Raptor Pharmaceutical Corp logoRaptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

Industry, Sector and Symbol:
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.45
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -43.75%
  • Return on Equity: -77.01%
  • Return on Assets: -15.64%
Debt:
  • Debt-to-Equity Ratio: 1.33%
  • Current Ratio: 3.57%
  • Quick Ratio: 3.30%
Misc:
  • Beta: 1.18
 
Frequently Asked Questions for Raptor Pharmaceutical Corp (NASDAQ:RPTP)

What is Raptor Pharmaceutical Corp's stock symbol?

Raptor Pharmaceutical Corp trades on the NASDAQ under the ticker symbol "RPTP."

How were Raptor Pharmaceutical Corp's earnings last quarter?

Raptor Pharmaceutical Corp (NASDAQ:RPTP) released its quarterly earnings data on Thursday, August, 4th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The firm had revenue of $32.05 million for the quarter, compared to the consensus estimate of $28.52 million. Raptor Pharmaceutical Corp had a negative net margin of 43.75% and a negative return on equity of 77.01%. The business's revenue was up 37.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.17) earnings per share. View Raptor Pharmaceutical Corp's Earnings History.

Where is Raptor Pharmaceutical Corp's stock going? Where will Raptor Pharmaceutical Corp's stock price be in 2017?

4 analysts have issued 12 month target prices for Raptor Pharmaceutical Corp's stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Raptor Pharmaceutical Corp's stock price to reach $7.75 in the next year. View Analyst Ratings for Raptor Pharmaceutical Corp.

Who are some of Raptor Pharmaceutical Corp's key competitors?

How do I buy Raptor Pharmaceutical Corp stock?

Shares of Raptor Pharmaceutical Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Raptor Pharmaceutical Corp's stock price today?

One share of Raptor Pharmaceutical Corp stock can currently be purchased for approximately $9.00.


MarketBeat Community Rating for Raptor Pharmaceutical Corp (NASDAQ RPTP)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Raptor Pharmaceutical Corp (NASDAQ:RPTP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.75 (13.89% downside)

Analysts' Ratings History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/16/2016Cowen and CompanyDowngradeOutperform -> Market Perform$9.00N/AView Rating Details
9/12/2016WedbushReiterated RatingNeutral$9.00 -> $4.00N/AView Rating Details
9/8/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/8/2016Citigroup Inc.DowngradeBuy -> Neutral$6.00 -> $8.00N/AView Rating Details
4/12/2016Leerink SwannReiterated RatingOutperform$11.00N/AView Rating Details
4/11/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
3/20/2016JMP SecuritiesDowngradeHoldN/AView Rating Details
8/22/2015Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Earnings by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Earnings History by Quarter for Raptor Pharmaceutical Corp (NASDAQ RPTP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.18)($0.16)$28.52 million$32.05 millionViewListenView Earnings Details
5/5/2016Q116($0.17)($0.17)$27.17 million$27.47 millionViewN/AView Earnings Details
2/25/2016Q415($0.19)($0.17)$26.08 million$24.67 millionViewListenView Earnings Details
11/5/2015Q315($0.18)($0.18)$24.25 million$25.80 millionViewListenView Earnings Details
8/6/2015Q215($0.21)($0.12)$21.40 million$23.30 millionViewN/AView Earnings Details
5/7/2015Q115($0.25)($0.24)$19.10 million$20.50 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.25)$20.12 million$17.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.18)($0.04)$18.90 million$23.80 millionViewN/AView Earnings Details
8/7/2014Q214($0.19)($0.15)$14.58 million$16.31 millionViewN/AView Earnings Details
5/8/2014Q413($0.17)($0.20)$11.81 million$12.10 millionViewN/AView Earnings Details
3/13/2014Q313($0.18)($0.19)$8.99 million$10.25 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.30)($0.30)ViewN/AView Earnings Details
3/14/2013Q1 2013($0.27)($0.37)ViewN/AView Earnings Details
1/9/2013Q1 2013($0.23)($0.26)$0.25 millionViewN/AView Earnings Details
11/14/2012Q412($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.88%
Insider Trades by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Institutional Ownership by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Insider Trades by Quarter for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2015Suzanne Louise BruhnDirectorSell18,258$12.47$227,677.26View SEC Filing  
9/2/2015Raymond AndersonDirectorSell4,916$12.51$61,499.16View SEC Filing  
8/31/2015Raymond AndersonDirectorSell8,084$12.52$101,211.68View SEC Filing  
7/1/2015Llew KeltnerDirectorSell50,000$16.05$802,500.00View SEC Filing  
6/18/2015Thomas E DaleyInsiderSell35,000$15.00$525,000.00View SEC Filing  
6/10/2015Suzanne Louise BruhnDirectorSell30,000$13.45$403,500.00View SEC Filing  
5/4/2015Richard L FranklinDirectorSell10,000$9.61$96,100.00View SEC Filing  
4/2/2015Richard L FranklinDirectorSell10,000$10.37$103,700.00View SEC Filing  
3/23/2015Christopher M StarrDirectorSell20,033$11.62$232,783.46View SEC Filing  
3/2/2015Richard L FranklinDirectorSell10,000$9.18$91,800.00View SEC Filing  
2/24/2015Christopher M StarrDirectorSell30,000$9.52$285,600.00View SEC Filing  
2/2/2015Richard L FranklinDirectorSell7,109$9.20$65,402.80View SEC Filing  
1/22/2015Christopher M StarrDirectorSell30,000$9.45$283,500.00View SEC Filing  
1/15/2015Christopher M StarrDirectorSell30,000$9.73$291,900.00View SEC Filing  
1/12/2015Raymond AndersonDirectorSell10,000$10.58$105,800.00View SEC Filing  
12/22/2014Christopher M StarrCEOSell30,000$9.00$270,000.00View SEC Filing  
12/15/2014Christopher M StarrCEOSell30,000$8.15$244,500.00View SEC Filing  
11/24/2014Christopher M StarrCEOSell30,000$9.97$299,100.00View SEC Filing  
10/22/2014Christopher M StarrCEOSell30,000$10.25$307,500.00View SEC Filing  
9/23/2014Christopher M StarrCEOSell30,000$10.21$306,300.00View SEC Filing  
9/16/2014Christopher M StarrCEOSell32,896$10.60$348,697.60View SEC Filing  
9/10/2014Raymond AndersonDirectorSell10,000$10.81$108,100.00View SEC Filing  
8/25/2014Erich SagerDirectorSell10,000$11.01$110,100.00View SEC Filing  
7/7/2014Llew KeltnerDirectorSell10,000$11.21$112,100.00View SEC Filing  
5/13/2014Georgia ErbezCFOBuy16,100$7.90$127,190.00View SEC Filing  
4/7/2014Vijay SamantDirectorSell5,000$8.59$42,950.00View SEC Filing  
3/17/2014Christopher StarrCEOSell19,316$10.79$208,419.64View SEC Filing  
1/13/2014Timothy WalbertDirectorSell5,520$15.06$83,131.20View SEC Filing  
1/9/2014Thomas DaleyInsiderSell15,000$14.17$212,550.00View SEC Filing  
1/7/2014Llew KeltnerDirectorSell10,000$13.25$132,500.00View SEC Filing  
1/2/2014Richard FranklinDirectorSell10,715$13.12$140,580.80View SEC Filing  
12/9/2013Vijay SamantDirectorSell5,000$13.86$69,300.00View SEC Filing  
11/13/2013Timothy WalbertDirectorSell5,521$12.44$68,681.24View SEC Filing  
11/4/2013Richard FranklinDirectorSell10,715$14.88$159,439.20View SEC Filing  
10/15/2013Christopher M StarrCEOSell25,000$13.77$344,250.00View SEC Filing  
10/14/2013Suzanne Louise BruhnDirectorSell2,760$13.58$37,480.80View SEC Filing  
10/7/2013Vijay SamantDirectorSell5,000$14.76$73,800.00View SEC Filing  
9/16/2013Christopher StarrCEOSell25,000$14.21$355,250.00View SEC Filing  
9/16/2013Erich SagerDirectorSell17,000$14.21$241,570.00View SEC Filing  
9/13/2013Suzanne Louise BruhnDirectorSell2,760$14.07$38,833.20View SEC Filing  
9/9/2013Richard L FranklinDirectorSell10,715$14.24$152,581.60View SEC Filing  
9/9/2013Thomas E DaleyInsiderSell25,000$14.28$357,000.00View SEC Filing  
8/30/2013Georgia ErbezCFOSell7,400$13.42$99,308.00View SEC Filing  
12/28/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  
11/26/2012Erich SagerDirectorSell11,279$5.00$56,395.00View SEC Filing  
9/12/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Latest Headlines for Raptor Pharmaceutical Corp (NASDAQ:RPTP)
Source:
DateHeadline
finance.yahoo.com logoRobbins Arroyo LLP: Acquisition of Raptor Pharmaceutical Corp. (RPTP) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoWhy Raptor Pharmaceuticals, OpenText, and Freeport-McMoRan Jumped Today
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoHorizon Pharma PLC -- Moody's: Horizon's Raptor acquisition credit negative
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoCompany News for September 13, 2016
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoMore Rare Disease Dealmaking to Follow Horizon's Raptor Deal
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoHorizon (HZNP) to Acquire Raptor for $800M, Stock Soars
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoRaptor Pharmaceutical Corp. Acquisition May Not Be in the Best Interests of RPTP Shareholders
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoBiotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Raptor Pharmaceutical Corp. to Horizon Pharma Plc for $9.00 Per Share
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoRaptor Pharmaceuticals' (RPTP) Shares March Higher, Can It Continue?
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoRAPTOR PHARMACEUTICAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Raptor Pharmaceutical Corp. (RPTP) Over the Proposed Sale of the Company to Horizon Pharma plc
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoNews of Acquisition Caused Horizon Pharma Stock to Rise
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoSHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Raptor Pharmaceutical Corp. -RPTP
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoKite, Anavex, G.W. Pharma Help Revive Biotech Sector Chemistry
finance.yahoo.com - April 7 at 12:22 PM
finance.yahoo.com logoHORIZON PHARMACEUTICAL LLC Financials
finance.yahoo.com - November 8 at 7:02 PM
biz.yahoo.com logoRAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Art
biz.yahoo.com - October 31 at 7:29 AM
streetinsider.com logoHorizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition
www.streetinsider.com - October 26 at 10:37 AM
biz.yahoo.com logoRAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - October 25 at 7:08 PM
streetinsider.com logoHorizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition - StreetInsider.com
www.streetinsider.com - October 25 at 12:18 PM
marketwatch.com logoHow These Biotech Stocks are Faring? -- Raptor Pharma, Amicus Therapeutics, Neuralstem, and Macrocure
www.marketwatch.com - October 21 at 7:10 PM
biz.yahoo.com logoRAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 20 at 8:37 AM
biz.yahoo.com logoRAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
biz.yahoo.com - October 11 at 7:28 PM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Raptor Pharmaceutical Corp. (RPTP)
finance.yahoo.com - October 6 at 6:50 PM
seekingalpha.com logoHorizon Pharma: Another Core Plus Biotech Worth Buying
seekingalpha.com - September 28 at 12:19 PM

Social

Chart

Raptor Pharmaceutical Corp (RPTP) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff